Free Trial

Inhibrx Biosciences (NASDAQ:INBX) Shares Up 8.7% - Here's Why

Inhibrx Biosciences logo with Medical background

Shares of Inhibrx Biosciences, Inc. (NASDAQ:INBX - Get Free Report) rose 8.7% on Tuesday . The stock traded as high as $20.16 and last traded at $19.94. Approximately 301,071 shares changed hands during mid-day trading, an increase of 211% from the average daily volume of 96,751 shares. The stock had previously closed at $18.35.

Analysts Set New Price Targets

Separately, JMP Securities reaffirmed a "market perform" rating on shares of Inhibrx Biosciences in a research note on Thursday, May 15th.

Check Out Our Latest Report on INBX

Inhibrx Biosciences Stock Up 0.3%

The stock's 50 day simple moving average is $13.91 and its two-hundred day simple moving average is $13.54. The firm has a market cap of $303.79 million, a P/E ratio of 0.18 and a beta of -0.04. The company has a debt-to-equity ratio of 1.04, a current ratio of 5.12 and a quick ratio of 5.12.

Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($2.80) EPS for the quarter, missing analysts' consensus estimates of ($2.55) by ($0.25). As a group, research analysts forecast that Inhibrx Biosciences, Inc. will post 104.88 earnings per share for the current year.

Institutional Trading of Inhibrx Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Sanofi purchased a new stake in shares of Inhibrx Biosciences in the 4th quarter worth $17,832,000. HighTower Advisors LLC purchased a new stake in Inhibrx Biosciences in the fourth quarter worth about $12,039,000. Walleye Capital LLC purchased a new stake in Inhibrx Biosciences in the fourth quarter worth about $8,932,000. Slotnik Capital LLC bought a new position in Inhibrx Biosciences during the 4th quarter worth about $5,975,000. Finally, Woodline Partners LP purchased a new position in Inhibrx Biosciences during the 1st quarter valued at about $5,015,000. Hedge funds and other institutional investors own 82.46% of the company's stock.

Inhibrx Biosciences Company Profile

(Get Free Report)

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.

Featured Articles

Should You Invest $1,000 in Inhibrx Biosciences Right Now?

Before you consider Inhibrx Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibrx Biosciences wasn't on the list.

While Inhibrx Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines